The Juvene IOL does not have FDA approval. As of early 2026, it remains an investigational device being studied in a U.S. pivotal clinical trial, and its manufacturer, LensGen, has not publicly announced a Premarket Approval application. No projected approval date is available, and only two accommodating intraocular lenses have ever cleared the U.S. market — Bausch + Lomb’s Crystalens in 2003 and its Trulign Toric variant in 2013. The Juvene is not yet among them.
Where the Juvene Stands in the FDA Pipeline
The FDA granted LensGen an Investigational Device Exemption in late 2021, which cleared the company to run a pivotal clinical trial in the United States.1Healio. FDA Approves IDE for Juvene IOL That trial, known as the Nirvana study, compares the Juvene against a standard monofocal IOL in cataract patients. Its purpose is to build the safety and effectiveness record needed for a Premarket Approval application, the most rigorous FDA pathway for medical devices and the one reserved for implants that sustain life or present significant risk.2U.S. Food and Drug Administration. Premarket Approval (PMA)
An IDE is not an approval. It is permission to gather human data. A PMA submission is the next milestone, and no public announcement has confirmed that the Nirvana trial has finished enrolling patients or begun submitting data to the agency. Whether the trial is still open to new participants as of early 2026 has not been publicly confirmed either.
Once a PMA is formally accepted, the FDA has 180 days to issue a decision. That clock can be extended by another 180 days if the agency requests significant new data or analysis.3U.S. Food and Drug Administration. PMA Review Process In practice, that means at least six months of review after a submission, and often closer to a year. Since no submission has been publicly confirmed, any timeline circulating online is speculation. Patients searching for a firm approval date should treat unofficial projections with caution.
What the Clinical Data Shows So Far
A separate earlier feasibility study (NCT05364658) involving 61 eyes at two sites in Mexico was completed in 2020 and produced published 12-month outcomes. That study is distinct from the larger U.S. pivotal trial the FDA will weigh for approval.4ClinicalTrials.gov. Study Details – A Clinical Evaluation of the LensGen Intraocular Lens Intraoperative complications in that study were rare, and visual outcomes supported the IDE application.5PubMed. Twelve-Month Clinical Outcomes After Implantation of a New, Modular, Anterior Shape-Changing Fluid Optic Intraocular Lens
Researchers later presented 36-month follow-up data at the 2023 American Society of Cataract and Refractive Surgery meeting. Bilateral patients achieved 20/20 distance vision, 20/25 intermediate vision, and J3 or better near vision, with results holding steady from year one through year three. Endothelial cell loss at three years was comparable to standard cataract surgery.6Ophthalmology Times. ASCRS Live: 36-Month Outcomes for the Juvene Modular Intraocular Lens Defocus curve testing showed the lens maintained usable 20/40 vision or better across roughly 3.5 diopters of range.7CRSToday. Update on Accommodating IOLs
Those numbers are encouraging, but they come from a relatively small number of eyes followed at a limited number of surgical centers. The U.S. pivotal trial has to show comparable safety and effectiveness across a larger, more diverse patient population before the FDA will consider approval. The most common adverse events in the 12-month published study were prolonged inflammation and cystoid macular edema, both of which resolved by the 12-month visit and both of which can also occur with standard cataract surgery.5PubMed. Twelve-Month Clinical Outcomes After Implantation of a New, Modular, Anterior Shape-Changing Fluid Optic Intraocular Lens Because the Juvene is a two-piece system that requires a fluid optic to dock into a base lens, the procedure is more complex than a standard IOL implantation, and the pivotal trial’s larger dataset should give a clearer picture of complication rates across different surgical teams.
How to Get a Juvene IOL Before Approval
Right now, the only route to a Juvene IOL is enrollment in the U.S. pivotal trial. Eligibility is narrow. Participants typically must have cataracts in both eyes, no prior corneal refractive surgery such as LASIK, no significant dry eye disease, and no corneal conditions that could affect visual outcomes. Anyone outside those criteria will not qualify, and there is no compassionate-use or off-label path for an investigational IOL.
The Juvene is not available through any surgeon outside the trial, and it is not available through medical tourism as an FDA-approved option, because it is not FDA-approved anywhere the FDA governs. Any advertisement suggesting otherwise inside the United States does not reflect the device’s current regulatory status.
What Availability Will Look Like After Approval
Even if the FDA grants a PMA, commercial availability will not be immediate. The review period alone runs 180 days from formal acceptance and can stretch to nearly a year with amendments.3U.S. Food and Drug Administration. PMA Review Process After approval, LensGen will need to train and certify surgeons on the two-piece implantation technique before they can offer it. A phased rollout is the typical pattern: a small group of experienced cataract surgeons at high-volume practices first, then broader release as training programs scale over the following months.
If cataract surgery is on your horizon in the next year or two, the practical question is whether to wait or move forward with an approved lens now. That is a conversation for a cataract surgeon who follows accommodating lens development. They can weigh your visual goals, the progression of your cataracts, and your timeline against a device whose availability date is still unknown.
What It Is Likely to Cost
The Juvene’s commercial price has not been announced. As a category, accommodating and multifocal IOLs currently run roughly $2,000 to $5,000 per eye above what insurance pays, and the Juvene’s novel technology and two-piece design could place it at the upper end of that range or beyond.
Medicare covers standard cataract surgery, including a conventional monofocal IOL, the facility fees, and the surgeon’s services. After you meet the Part B deductible, you pay 20% of the Medicare-approved amount.8Medicare.gov. Cataract Surgery – Medicare The premium charged for an advanced lens upgrade is considered elective and falls outside that coverage. Some Medicare Advantage plans offer limited premium lens benefits, so calling your plan before surgery is worth the time.9CMS. Billing and Coding: Cataract Surgery (A59805) Most commercial insurance follows the same pattern: the basic procedure is covered, the lens upgrade is not.
Out-of-pocket costs for premium IOLs qualify as eligible medical expenses under both Health Savings Accounts and Flexible Spending Accounts. For 2026, the IRS allows HSA contributions of up to $4,400 for self-only coverage and $8,750 for family coverage.10IRS. IRS Notice: 2026 HSA Contribution Limits Building an HSA balance now is one of the few ways to pay for a premium lens with pre-tax dollars if and when the Juvene reaches the market.